

Crucial Conversations in Cancer Care:  
Management of Patients Undergoing Immunotherapy  
Treatments

This activity is provided by:



This activity is supported by an educational grant  
from Kite Pharmaceuticals.

**Date**                    **Saturday, September 8, 2018**

**Faculty**                **Patricia A. Mangan, MSN, CRNP**  
Nurse Lead of the Hematologic Malignancies and Stem Cell Transplant Programs  
Abramson Cancer Center  
University of Pennsylvania  
Philadelphia, PA

**Location**             **JW Marriott Los Angeles LA Live**  
Los Angeles, CA

**Target Audience**

This activity has been designed to meet the educational needs of oncology nurses and nurse practitioners involved in the care of patients that experience chemotherapy-induced nausea and vomiting as a result of their treatment.

**Overview**

As immunotherapies continue to transition from clinical trials to the standard of care for some cancers, nurses must be knowledgeable about the diverse categories and classes of agents in this field and deliver safe, effective, and evidence-based care to their patients. Nurses' most important roles in the immunotherapy evolution are safe administration of these agents and patient education. Nurses should also be a voice for high-quality cancer care and play an active role in policy decisions surrounding this novel therapy. The educational activities will present evidence-based and clinically informed approaches to the management of patients across the lifespan, including strategies for nursing education, preparation of clinical settings to provide immunotherapy and deliver focused care to patients receiving these therapies, algorithms to guide toxicity management, and guidelines for safe handling and administration of these agents to protect patients and healthcare providers.

**Learning Objectives**

Upon completion of this educational activity, learners should be better able to:

- Describe the mechanisms of action of newer immunotherapy agents
- Identify immune-related adverse events and the mechanisms behind them
- Implement early assessment and management strategies to address immune-related AEs
- Identify crucial conversations to engage in shared decision making addressing treatments and patient care

## Activity Agenda

Pre-activity survey

### **Segment 1:** Understanding Immunotherapies

Classes and Mechanisms of Action

Current and Emerging Areas of Treatment

### **Segment 2:** Understanding Toxicities and Immune-Related Adverse Events

Class Toxicities

Therapy-specific Toxicities

### **Segment 3:** Assessing and Managing Toxicities Related to Immunotherapy

Approaches to Assessing Patients Receiving Immunotherapy

Management and Interventions

### **Segment 4:** Patient Education and Tools to Facilitate Early Detection

Post-activity survey (with discussion of rationale)

Q&A

**To promote active learning and engage learners, audience polling questions and a discussion case have been incorporated into the activity design.**

## Accreditation and Credit Statements

American Academy of CME, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. Provider is certified by the California Board of Nursing. American Academy of CME, Inc. designates this educational activity for 1.0 contact hour (pharmacotherapeutic contact hour .7).

### *California*

Provider approved by the California Board of Registered Nursing, Provider Number CEP16993 for 1.0 contact hours.

## Method of Participation

There are no fees for participating/receiving CE credit for this activity. In order to receive CE contact hours, learners must:

- 1) Review the CE information including the learning objectives and disclosure statements;
- 2) Attend the activity and document attendance;
- 3) Complete and return the course evaluation form

Upon successfully completing the activity evaluation, your certificate will be email to you in approximately 30 days.

## Disclosures

According to the disclosure policy of American Academy of CME, Inc., all faculty, planning committee members, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. Disclosures will be made known to participants prior to the activity.

The opinions expressed in this educational activity are those of the faculty, and do not represent those of Academy or American Nurses Credentialing Center's Commission on Accreditation. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information.

## **Course Faculty**

Patricia A. Mangan, MSN, CRNP  
Promotional Speaker's Bureau – Kite Pharmaceuticals

## **Planning Committee**

John JD Juchniewicz, MCIS, CHCP, Paul J. Minitzer, MS, Natalie Kirkwood, RN, BSN, JD, Lead Nurse Planner, and Wendy Gloffke, PhD, American Academy of CME: No relevant financial relationships with any commercial interests.

Eric Parsons RN, Research Nurse Leukemia Program, Taussig Cancer Center, Cleveland Clinic has no relevant financial relationships with any commercial interests.

Laura Wood, RN, MSN, OCN, Renal Cancer Research Coordinator, Cleveland Clinic Taussig Cancer Center has the following disclosures:

Promotional Speakers Bureau: Bristol-Myers Squibb, Merck, Pfizer

## **Off-Label Usage Disclosure**

This educational activity may contain discussion of published and/or investigational uses of agents not indicated by the FDA. Faculty have been asked to disclose off-label and/or investigational uses if they are mentioned. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the American Academy of CME. Before using any medication, learners should consult primary references and full prescribing information. Please refer to official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, learners should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this activity. American Academy of CME requires faculty to provide the level of evidence for patient care recommendation made during their presentations.

Per regulatory guidelines, the educational grant used to support this activity may only be used for medical professionals attending the presentation. Our grant funding does not allow for participation by non-healthcare providers and/or guests. If you have questions or comments about this activity, contact [CEServices@academycme.org](mailto:CEServices@academycme.org).

## **Faculty Biography**

Patricia A. Mangan, MSN, CRNP, is Nurse Lead of the Hematologic Malignancies and Stem Cell Transplant Programs at the Abramson Cancer Center of the University of Pennsylvania in Philadelphia. In addition, she works in collaborative practice with Edward A. Stadtmauer, MD, focusing on the care of patients with multiple myeloma and other blood cancers. She is also a Clinical Academic Associate at the University of Pennsylvania's School of Nursing. Ms. Mangan is a member of the Nursing Leadership Board of the International Myeloma Foundation.

She earned her master of science in nursing degree from the University of Pennsylvania and is a board-certified registered nurse practitioner (CRNP) and clinical nurse specialist.

An invited speaker on a broad number of topics that deal with bone marrow transplant, cellular immunotherapy and the care of patients with hematologic malignancies, Patricia Mangan has lectured on both the local, national and international level. The results of her work have appeared in such peer-reviewed journals as *Blood*, *Nursing*, *Bone Marrow Transplant*, *Clinical Journal of the Oncology Nursing Society (CJON)*, *The Lancet Haematology* and *The Nurse Practitioner*.